FrançaisAre analysts right about Harmony Biosciences Holdings, Inc. (HRMY)?
📈 See the interactive version (live chart) →
Historical analyst accuracy
For Harmony Biosciences Holdings, Inc., we replayed every analyst price target of the past 12 months and measured the real outcome: 16% were profitable, average return -3% (101 calls). At 3 months: +0% average return (34% profitable). The higher the %, the more often analysts were right on this stock.
Most reliable analysts on this stock (past track record)
Their past track record on this stock (targets replayed against real prices) — not a forecast of what will happen.
| Analyst / broker | Calls i | % profitable i | Avg return i |
|---|---|---|---|
| Needham | 38 | 10% | -4% |
| Mizuho | 17 | 12% | -10% |
| Cantor Fitzgerald | 8 | 0% | -7% |
| HC Wainwright & Co. | 7 | 29% | +4% |
| Raymond James | 6 | 50% | +4% |
Frequently asked questions
Is Harmony Biosciences Holdings, Inc. a buy right now?
The analyst consensus on Harmony Biosciences Holdings, Inc. (HRMY) is "Buy" (14 bullish, 1 bearish calls over 12 months). This is not advice: historically, 16% of their targets on this stock turned out profitable over 1 year.
What is Harmony Biosciences Holdings, Inc.'s price target?
The median 12-month price target is $50.50 (+31% vs $38.59), ranging from $34.00 to $60.00 (6 analysts).
Are analysts accurate on Harmony Biosciences Holdings, Inc.?
Over 1 year, 16% of analyst targets on Harmony Biosciences Holdings, Inc. were profitable, for an average return of -3% (across 101 timestamped calls). This is JPI Invest's accuracy metric.
What is the Harmony Biosciences Holdings, Inc. stock forecast?
Analysts target a median of $50.50 within 12 months, i.e. +31% vs the current price. The most bullish targets $60.00, the most cautious $34.00.
What is the Harmony Biosciences Holdings, Inc. stock forecast for 2026 or long term (2030)?
Note: analyst targets are 12-month (median $50.50, +31%), NOT 2030. No reliable 5-10 year price forecast exists (« 2030 prediction » models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (16%), and the stock's past trajectory.
Is Harmony Biosciences Holdings, Inc. overvalued?
Detailed valuation data for Harmony Biosciences Holdings, Inc. is available in the interactive analysis.
📊 See the full interactive analysis of Harmony Biosciences Holdings, Inc. →
What is JPI Invest?
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best — on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
- 🏆 Analyst leaderboard by real reliability (beating their sector, not just riding the rally)
- 🎯 What to buy: 3 backtested methods over 6 years, from cautious to aggressive
- 💬 AI assistant: ask anything about any stock, with the numbers
- 📊 Portfolio tracking + 🔔 price alerts by email
⚠️ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.